Why Peptides Are Central to Modern GLP-1 and Incretin Drug Development

1. Metabolic regulation is a network of peptide signals

Many closely watched metabolic drug programs are peptides or molecules engineered from natural peptide-hormone biology.

Semaglutide is a GLP-1 analogue, tirzepatide activates GIP and GLP-1 receptors, CagriSema combines GLP-1 and amylin pathways, and retatrutide is designed around GIP, GLP-1 and glucagon receptors.

After food intake, the gastrointestinal tract and pancreas release signals including GLP-1, GIP, PYY and amylin.

These participate in overlapping processes involving satiety, gastric motility, nutrient handling, insulin secretion and glucagon regulation.

The modern strategy is not simply to suppress appetite, but to reproduce, modify or combine selected parts of this network with a drug-like exposure profile.

2. Receptor selectivity must be demonstrated, not assumed

Many peptides interact through relatively large and defined receptor-binding surfaces.

This can support high receptor selectivity, but it is not universal.

Sequence changes, chemical modifications, concentration, metabolites and receptor homology can all alter pharmacology.

GLP-1 receptor agonism can stimulate insulin secretion in a glucose-dependent manner.

Product labels nevertheless warn that hypoglycemia risk can rise when relevant medicines are combined with insulin or insulin secretagogues.

That product- and regimen-specific context is why a pharmacological mechanism should not be converted into a blanket safety claim.

Modern programs also deliberately move beyond single-receptor selectivity.

Tirzepatide activates GIP and GLP-1 receptors, while retatrutide adds glucagon-receptor activity.

A multi-agonist program may require receptor-specific potency methods, a justified activity ratio and evidence that manufacturing variability does not shift the intended balance.

3. Half-life engineering turns short-lived hormones into drug candidates

Native, biologically active GLP-1 is rapidly inactivated, with early human studies showing extensive DPP-4-mediated degradation and a functional half-life measured in minutes.

A natural signal useful for short physiological pulses is not automatically suitable for sustained pharmaceutical exposure.

Semaglutide includes amino-acid substitutions that improve resistance to metabolic degradation and a fatty-diacid side chain attached through a linker to increase albumin affinity.

Tirzepatide also contains a fatty diacid that enables albumin binding and contributes to prolonged half-life according to current FDA labeling.

Other programs use lipidation, fusion proteins, Fc or albumin-binding constructs, cyclization, backbone modification or antibody–peptide conjugation.

Each creates analytical and manufacturing questions around accumulation, degradation products, aggregation, immunogenicity, formulation concentration and device design.

4. Multi-agonists and combinations expand the product-design space

The progression from single GLP-1 receptor agonists to dual agonists, triple agonists and amylin combinations reflects the networked biology of metabolic regulation.

Prescription finished products containing tirzepatide have been approved by the U.S.

FDA for defined indications, while CagriSema and retatrutide remained investigational in the status sources used for this article.

These approaches are structurally different.

A unimolecular dual or triple agonist must encode the intended receptor activity in one molecular construct.

A fixed-dose combination must control two active components, their ratio, stability and delivery.

An antibody–peptide conjugate adds conjugation-site, loading, linker and higher-order-structure considerations.

The clinical hypothesis may concern complementary biology, but the development package must show that the manufactured product consistently expresses that hypothesis.

Potency methods, impurity controls and stability-indicating assays are therefore part of pharmacology, not merely downstream checks.

5. Oral peptide delivery is possible, but molecule- and formulation-specific

Peptides face two major oral-delivery barriers: degradation in the gastrointestinal environment and limited transport across the epithelium.

Oral semaglutide demonstrated that those barriers can be addressed for a specific molecule through co-formulation with the absorption enhancer SNAC.

Clinical and preclinical work showed localized semaglutide absorption in the stomach near the tablet surface.

The formulation changes the local environment and facilitates transcellular absorption.

This is a product-specific drug–excipient system, not evidence that an unmodified peptide powder or conventional tablet will be orally bioavailable.

Development continues across absorption enhancers, enteric systems, nanoparticles, enzyme protection and other platforms.

Low and variable bioavailability, food and water effects, excipient exposure, dosage-form stability and scale-up reproducibility remain central challenges.

Injectable and oral formats are likely to coexist according to the molecule and target product profile.

6. CMC determines whether peptide pharmacology becomes a reproducible product

A peptide candidate is defined by more than its nominal sequence.

Teams must control stereochemistry, modified residues, termini, salt or counter-ion form, conjugated moiety and any disulfide or cyclic structure.

The impurity map may need to cover deletion and insertion sequences, epimers, oxidation, deamidation, aggregation, conjugation variants and process-related residues.

Analytical strategy extends beyond a headline HPLC purity value.

Identity, related substances, mass confirmation, water, counter-ions, residual solvents, potency, higher-order behavior and stability may all be relevant, depending on the molecule and development stage.

Scale-up adds questions about synthesis route, raw-material controls, purification selectivity, yield, hold times, formulation compatibility, reference standards and method transfer.

Compelling receptor pharmacology can still fail if the candidate cannot be produced and characterized reproducibly.

7. A practical B2B due-diligence checklist

Before a peptide program moves into sourcing or process evaluation, the brief should identify the exact molecule and modification pattern, material category, intended use, development stage, target jurisdiction and required documentation.

GLP-1 peptide is not a sufficiently precise sourcing description.

The team should define target specification, analytical methods, reference-standard strategy, formulation route, stability conditions, expected scale, regulatory owner and IP/FTO owner.

Approved drug, investigational API, reference material, research material and development capability are legally and technically different categories.

Peptide and incretin biology provide a powerful design space, but receptor activity is only one part of a developable pharmaceutical product.